Trials / Completed
CompletedNCT00001155
Treatment of Wegener's Granulomatosis With Cyclophosphamide
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · NIH
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Detailed description
The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy. Age Range: greater than 1 year
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cyclophosphamide |
Timeline
- Start date
- 1976-02-01
- Completion
- 2002-02-01
- First posted
- 1999-11-04
- Last updated
- 2008-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00001155. Inclusion in this directory is not an endorsement.